Predictive Oncology Inc

+0.02 (+5.81%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)29.66M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.5 Million
Adjusted EPS-$0.03
See more estimates
10-Day MA$0.40
50-Day MA$0.54
200-Day MA$0.89
See more pivots

Predictive Oncology Inc Stock, NASDAQ:POAI

2915 Commers Drive, Suite 900, Eagan, Minnesota 55121
United States of America
Phone: +1.651.389.4800
Number of Employees: 32


Predictive Oncology, Inc. engages in the application of artificial intelligence medicine business and provision of cleared STREAMWAY System for automated, direct-to-drain medical fluid disposal and associated products. It operates through the following segments: Helomics, zPREDICTA, Skyline, Soluble, and Corporate. The Helomics segment includes clinical testing and contract research services that include the application of AI. The zPREDICTA segment specializes in organ-specific disease models that provide 3D reconstruction of human tissues accurately representing each disease state and mimicking drug response enabling accurate testing of anticancer agents. The Skyline segment is composed of the STREAMWAY System product sales, and its TumorGenesis subsidiary is included within corporate. The Soluble segment provides services using an automated system that conducts self-interaction chromatography screens, using additives and excipients commonly included in protein formulations resulting in soluble and physically stable formulations for biologics. The company was founded by Lawrence W. Gadbaw, Peter L. Morawetz, and Jeffrey K. Drogue on April 23, 2002 and is headquartered in Eagan, MN.